InspireMD Inc. buy stratec
Summary
This prediction ended on 10.01.19 with a price of €110.25. Massive losses of -98.00% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| InspireMD Inc. | -11.538% | -11.538% | -51.271% | 11.650% |
| iShares Core DAX® | 3.075% | 0.488% | 11.388% | 50.357% |
| iShares Nasdaq 100 | 2.876% | 0.081% | 22.472% | 81.104% |
| iShares Nikkei 225® | 5.981% | 3.033% | 41.000% | 59.466% |
| iShares S&P 500 | 2.231% | 0.046% | 18.100% | 60.472% |
Comments by stratec for this prediction
In the thread InspireMD Inc. diskutieren
InspireMD expects Q4 2017 sales of ~$833K (+159%)
The company says the CGuard* stent is designed to prevent embolization (blocking a blood vessel) by
trapping potential emboli against the arterial wall while maintaining excellent blood flow.
* Das CGuardTM Embolic Prevention System (EPS) wurde entwickelt, um eine peri-prozedurale und späte Embolisation zu verhindern, indem mögliche Emboli gegen die Arterienwand abgefangen werden, während gleichzeitig eine ausgezeichnete Perfusion zu der äußeren Halsschlagader und den
Nebengefäßen aufrechterhalten wird.


